

Yi-Bin Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6966865/publications.pdf>

Version: 2024-02-01

241
papers

11,054
citations

36203

51
h-index

37111

96
g-index

243
all docs

243
docs citations

243
times ranked

11749
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant. <i>New England Journal of Medicine</i> , 2019, 381, 2043-2050.	13.9	767
2	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	13.9	488
3	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
4	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
5	B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 327-340.	2.1	327
6	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	0.8	258
7	Primary Effusion Lymphoma. <i>Oncologist</i> , 2007, 12, 569-576.	1.9	236
8	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
9	Axicabtagene CiloleuceL in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	0.8	216
10	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	0.6	214
11	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
12	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning; a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	2.2	200
13	Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. <i>Blood</i> , 2019, 134, 860-866.	0.6	178
14	Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood</i> , 2020, 135, 1739-1749.	0.6	176
15	Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 783-784.	13.9	170
16	Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. <i>Blood Advances</i> , 2018, 2, 745-753.	2.5	167
17	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
18	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2016, 175, 496-504.	1.2	162

#	ARTICLE	IF	CITATIONS
19	Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 565-574.	2.0	160
20	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	0.8	149
21	Sequence-Based Discovery of <i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. <i>New England Journal of Medicine</i> , 2013, 369, 517-528.	13.9	148
22	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
23	Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. <i>Blood</i> , 2012, 119, 1972-1980.	0.6	136
24	Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.	2.0	133
25	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	0.6	129
26	Acquired Hypocalciuric Hypercalcemia Due to Autoantibodies against the Calcium-Sensing Receptor. <i>New England Journal of Medicine</i> , 2004, 351, 362-369.	13.9	125
27	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. <i>Leukemia</i> , 2014, 28, 658-665.	3.3	121
28	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
29	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
30	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
31	Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 805-812.	2.0	79
32	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
33	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	0.8	79
34	Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1374-1380.	2.0	77
35	Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 76-83.	2.0	76
36	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75

#	ARTICLE	IF	CITATIONS
37	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018, 132, 92-92.	0.6	74
38	Impact of preâ€transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
39	MyD88-Dependent TLR1/2 Signals Educate Dendritic Cells with Gut-Specific Imprinting Properties. <i>Journal of Immunology</i> , 2011, 187, 141-150.	0.4	70
40	The role of <scp>FLT</scp>3 inhibitors in the treatment of <scp>FLT</scp>3â€mutated acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 330-336.	1.1	68
41	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 1656-1669.	2.5	68
42	Trends in allâ€cause mortality among patients with chronic myeloid leukemia. <i>Cancer</i> , 2013, 119, 2620-2629.	2.0	67
43	Prognostic factors for patients with diffuse large <scp>B</scp> cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. <i>British Journal of Haematology</i> , 2013, 160, 608-617.	1.2	67
44	Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 642-646.	2.0	64
45	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
46	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. <i>Blood</i> , 2022, 139, 2306-2315.	0.6	62
47	Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2022, 40, 3985-3993.	0.8	62
48	Phase 2 trial of highâ€dose rituximab with highâ€dose cytarabine mobilization therapy and highâ€dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by nonâ€Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 226-233.	2.0	61
49	Increased Foxp3 + Helios + Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 625-634.	2.0	59
50	Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2011, 53, e77-e80.	2.9	56
51	Risk Factors for Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1190-1196.	2.0	55
52	The addition of sirolimus to the graftâ€versusâ€host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
53	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
54	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52

#	ARTICLE	IF	CITATIONS
55	Biomarkers for acute GVHD: can we predict the unpredictable?. Bone Marrow Transplantation, 2013, 48, 755-760.	1.3	49
56	Enzastaurin. Expert Opinion on Investigational Drugs, 2008, 17, 939-944.	1.9	47
57	Donor-Derived Second Hematologic Malignancies after Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1025-1031.	2.0	47
58	Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood, 2012, 119, 4083-4090.	0.6	47
59	Expression of CD30 in patients with acute graft-versus-host disease. Blood, 2012, 120, 691-696.	0.6	47
60	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology, 2016, 175, 841-850.	1.2	47
61	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. Biology of Blood and Marrow Transplantation, 2019, 25, 720-727.	2.0	47
62	Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplantation, 2018, 53, 199-206.	1.3	46
63	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Advances, 2020, 4, 122-126.	2.5	46
64	Bleomycin-Induced Flagellate Erythema. Journal of Clinical Oncology, 2007, 25, 898-900.	0.8	45
65	Up-Regulation of $\alpha 4 \beta 7$ Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1066-1076.	2.0	45
66	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
67	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	3.3	45
68	Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e17-e22.	2.0	44
69	Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 981-987.	2.0	43
70	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. Bone Marrow Transplantation, 2017, 52, 400-408.	1.3	42
71	Successful anti-CD19 CAR cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer, 2019, 125, 3692-3698.	2.0	42
72	High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer, 2017, 123, 3073-3079.	2.0	41

#	ARTICLE	IF	CITATIONS
73	Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach. <i>Human Immunology</i> , 2018, 79, 258-265.	1.2	40
74	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38
75	Allotransplantation for Patients Age \geq 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
76	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
77	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015, 50, 197-203.	1.3	37
78	Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2016, 51, 58-66.	1.3	36
79	Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1741-1747.	2.0	36
80	Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1447-1454.	2.0	35
81	Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1130-1136.	0.6	35
82	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2017, 129, 3256-3261.	0.6	34
83	Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 1627-1632.	3.3	33
84	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
85	Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. <i>Advances in Hematology</i> , 2016, 2016, 1-8.	0.6	33
86	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	1.7	33
87	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
88	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
89	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2373-2380.	2.0	31
90	FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?. <i>Journal of Clinical Oncology</i> , 2019, 37, 1604-1607.	0.8	29

#	ARTICLE	IF	CITATIONS
91	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
92	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. <i>Haematologica</i> , 2018, 103, 522-530.	1.7	28
93	Pilot study of a multimodal intervention to enhance sexual function in survivors of hematopoietic stem cell transplantation. <i>Cancer</i> , 2018, 124, 2438-2446.	2.0	28
94	Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2234-2242.	2.0	28
95	Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 3136-3140.	2.5	28
96	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
97	Treatment of FLT3-ITD acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2011, 1, 175-89.	0.6	28
98	Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. <i>Oncologist</i> , 2012, 17, 80-90.	1.9	27
99	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e14-e25.	2.2	27
100	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2018, 131, 1073-1080.	0.6	26
101	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 4136-4146.	2.5	26
102	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019, 3, 875-883.	2.5	25
103	BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML. <i>Blood</i> , 2019, 134, 4602-4602.	0.6	25
104	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with Î±-1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	2.5	24
105	The evolving landscape in the therapy of acute myeloid leukemia. <i>Protein and Cell</i> , 2013, 4, 735-746.	4.8	23
106	Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. <i>Leukemia Research</i> , 2014, 38, 773-780.	0.4	23
107	Isocitrate dehydrogenase 1 and 2 mutations, 2â€œhydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 541-549.	2.0	23
108	Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. <i>Oncologist</i> , 2022, 27, 685-693.	1.9	23

#	ARTICLE	IF	CITATIONS
109	Expression of $\alpha 4 \beta 7$ integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplantation, 2013, 48, 598-603.	1.3	22
110	Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist, 2018, 23, 624-630.	1.9	21
111	Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia, 2008, 22, 31-41.	3.3	20
112	Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Advances, 2017, 1, 1919-1922.	2.5	20
113	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematology, the, 2016, 3, e276-e283.	2.2	19
114	Non-invasive detection of severe neutropenia in chemotherapy patients by optical imaging of nailfold microcirculation. Scientific Reports, 2018, 8, 5301.	1.6	19
115	Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned. Transplantation, 2019, 103, 2366-2372.	0.5	19
116	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology, the, 2020, 7, e122-e133.	2.2	19
117	Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2015, 21, 1583-1588.	2.0	18
118	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 2216-2223.	2.0	18
119	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood, 2019, 134, 211-215.	0.6	18
120	Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance. Blood, 2013, 122, 741-741.	0.6	18
121	The expanding frontier of hematopoietic cell transplantation. Cytometry Part B - Clinical Cytometry, 2012, 82B, 271-279.	0.7	17
122	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. American Journal of Hematology, 2014, 89, 1097-1101.	2.0	16
123	Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 730-734.	2.0	16
124	More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2101-2102.	13.9	16
125	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Blood Advances, 2017, 1, 2473-2482.	2.5	16
126	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. Leukemia, 2020, 34, 1898-1906.	3.3	16

#	ARTICLE	IF	CITATIONS
127	miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. <i>Cellular and Molecular Biology</i> , 2015, 61, 12-6.	0.3	16
128	Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2134-2140.	2.0	15
129	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2383-2387.	2.0	15
130	A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	2.0	15
131	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
132	A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 3964-3964.	0.6	15
133	A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). <i>Blood</i> , 2016, 128, 390-390.	0.6	15
134	Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 186-192.	1.2	14
135	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 80-85.	2.0	14
136	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	2.0	14
137	High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 884-888.	0.2	14
138	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	0.8	14
139	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
140	Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 601-601.	0.6	13
141	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
142	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	0.6	12
143	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	2.5	12
144	Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 789-796.	0.6	11

#	ARTICLE	IF	CITATIONS
145	Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?. Bone Marrow Transplantation, 2016, 51, 1121-1126.	1.3	11
146	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplantation, 2019, 54, 497-507.	1.3	11
147	T Cell Clonal Dynamics Determined by High-Resolution TCR- \hat{I}^2 Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1567-1574.	2.0	11
148	JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. Med, 2022, 3, 42-57.e5.	2.2	11
149	How I treat with maintenance therapy after allogeneic \hat{A} HCT. Blood, 2023, 141, 39-48.	0.6	11
150	High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2011, 52, 1363-1366.	0.6	10
151	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen \hat{A} Matched Grafts. Biology of Blood and Marrow Transplantation, 2017, 23, 126-133.	2.0	10
152	Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 479.e1-479.e7.	0.6	10
153	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 988.e1-988.e7.	0.6	10
154	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood, 2018, 132, 705-705.	0.6	10
155	Emerging approaches to improve allogeneic hematopoietic cell transplantation outcomes for nonmalignant diseases. Blood, 2022, 139, 3583-3593.	0.6	10
156	Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT). Blood, 2021, 138, 409-409.	0.6	10
157	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 766-766.	0.6	9
158	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Advances, 2022, 6, 3707-3715.	2.5	9
159	Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1836-1840.	2.0	8
160	Automated detection of neutropenia using noninvasive video microscopy of superficial capillaries. American Journal of Hematology, 2019, 94, E219-E222.	2.0	8
161	A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 2477-2488.	1.3	8
162	Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT). Transplantation and Cellular Therapy, 2021, , .	0.6	8

#	ARTICLE	IF	CITATIONS
163	G-CSF Indirectly Induces Apoptosis of Osteoblasts During Hematopoietic Stem Cell Mobilization. <i>Clinical and Translational Science</i> , 2017, 10, 287-291.	1.5	7
164	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. <i>Bone Marrow Transplantation</i> , 2020, 55, 758-762.	1.3	7
165	Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 496.e1-496.e5.	0.6	7
166	Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1. <i>Blood</i> , 2015, 126, 864-864.	0.6	7
167	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
168	Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 687-705.	0.9	6
169	Current Approaches to Transplantation for FLT3-ITD AML. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 1-8.	1.2	6
170	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	0.6	6
171	Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E331-E333.	2.0	5
172	Ciprofloxacin prophylaxis is associated with a lower incidence of gram-negative bacteremia in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2319-2321.	1.3	5
173	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	0.6	5
174	A Multicenter Phase I/II Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 860-860.	0.6	5
175	Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies. <i>Blood</i> , 2021, 138, 653-653.	0.6	5
176	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 699-707.	0.9	4
177	Declining bone marrow harvest quality over 24 years: a single institution experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 983-985.	1.3	4
178	Prophylactic Rituximab After Allogeneic Stem Cell Transplantation Prevents Steroid-Requiring Chronic Graft-Vs.Host Disease. <i>Blood</i> , 2010, 116, 214-214.	0.6	4
179	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
180	Case 24-2012. <i>New England Journal of Medicine</i> , 2012, 367, 552-563.	13.9	3

#	ARTICLE	IF	CITATIONS
181	Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, e70-e72.	0.8	3
182	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. <i>Bone Marrow Transplantation</i> , 2020, 55, 804-810.	1.3	3
183	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	0.6	3
184	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013, 122, 695-695.	0.6	3
185	The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. <i>Blood</i> , 2013, 122, 704-704.	0.6	3
186	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 265-265.	0.6	3
187	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
188	Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenita. <i>Annals of Hematology</i> , 2022, 101, 907-909.	0.8	3
189	Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1296-1296.	0.6	3
190	Expression of $\alpha 4 \beta 7$ Integrin on Memory CD8+ T-Cells Is Increased in Patients at Presentation of Acute Intestinal Graft-Vs-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S221.	2.0	2
191	The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1977-1979.	0.6	2
192	Hydroxyurea for Treatment of Nephrotic Syndrome Associated With Polycythemia Vera. <i>American Journal of Kidney Diseases</i> , 2016, 68, 465-468.	2.1	2
193	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1178-1180.	1.3	2
194	Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Oncologist</i> , 2021, 26, e2082-e2085.	1.9	2
195	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	0.6	2
196	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2177-2177.	0.6	2
197	Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit. <i>Blood</i> , 2015, 126, 2104-2104.	0.6	2
198	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). <i>Blood</i> , 2015, 126, 1930-1930.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Case 23-2015: A Woman with Headache, Cognitive Impairment, and Weakness. <i>New England Journal of Medicine</i> , 2015, 373, 1983-1983.	13.9	1
200	Case 11-2017 " A 61-Year-Old Woman with Leg Swelling, Back Pain, and Hydronephrosis. <i>New England Journal of Medicine</i> , 2017, 376, 1461-1471.	13.9	1
201	Acute Myeloid Leukemia Presenting Less Than 3 Weeks After Living Donor Kidney Transplant: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 1360-1364.	0.3	1
202	A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results. <i>Blood</i> , 2018, 132, 605-605.	0.6	1
203	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. <i>Blood</i> , 2019, 134, 3275-3275.	0.6	1
204	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	0.6	1
205	A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies. <i>Blood</i> , 2015, 126, 389-389.	0.6	1
206	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
207	Reduced Intensity Conditioning (RIC) with Double Umbilical Cord Blood Transplantation Has Similar Outcomes Compared to RIC Transplantation From Related or Unrelated Adult Donors. <i>Blood</i> , 2010, 116, 2367-2367.	0.6	1
208	Patient Characteristics Associated With Receiving Hematopoietic Stem Cell Transplantation In An Older, Transplant-Appropriate MDS Cohort: The MDS-TAO Study. <i>Blood</i> , 2013, 122, 2929-2929.	0.6	1
209	Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations. <i>Blood</i> , 2014, 124, 1045-1045.	0.6	1
210	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571.	0.6	1
211	Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure. <i>Leukemia Research Reports</i> , 2022, 17, 100302.	0.2	1
212	Acute GVHD: do we trust our gut?. <i>Blood</i> , 2021, 137, 1447-1448.	0.6	0
213	Case 26-2021: A 49-Year-Old Man with Relapsed Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2021, 385, 834-843.	13.9	0
214	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2021, 109, 106625.	0.4	0
215	Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5124-5124.	0.6	0
216	Busulfan Dosing May Affect Survival Following Reduced Intensity Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia.. <i>Blood</i> , 2009, 114, 4328-4328.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant. <i>Blood</i> , 2010, 116, 903-903.	0.6	0
218	Do Older Patients With Moderate-Severe Chronic Graft-Versus-Host Disease Differ From Younger Patients?. <i>Blood</i> , 2013, 122, 725-725.	0.6	0
219	Comparison of Umbilical Cord Blood to Adult Related and Unrelated Donors. <i>Pancreatic Islet Biology</i> , 2014, , 235-255.	0.1	0
220	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 3961-3961.	0.6	0
221	Serum Uric Acid Levels during Allogeneic Hematopoietic Cell Transplantation and Subsequent Graft Versus Host Disease. <i>Blood</i> , 2014, 124, 2493-2493.	0.6	0
222	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. <i>Blood</i> , 2015, 126, 2126-2126.	0.6	0
223	Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report. <i>Blood</i> , 2015, 126, 3154-3154.	0.6	0
224	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3310-3310.	0.6	0
225	Risk Factors and Impact of Neurological Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5742-5742.	0.6	0
226	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	0.6	0
227	The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 5784-5784.	0.6	0
228	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	0.6	0
229	Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4587-4587.	0.6	0
230	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2019, 1, 201-204.	0.7	0
231	Post-Transplant Cyclophosphamide in Allogeneic Bone Marrow Transplantation for the Treatment of Benign Hematologic Diseases. <i>Blood</i> , 2019, 134, 1978-1978.	0.6	0
232	Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program. <i>Blood</i> , 2019, 134, 5371-5371.	0.6	0
233	Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
234	Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program. <i>Blood</i> , 2020, 136, 39-40.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
236	A glimpse into what happens after PTCy. <i>Blood</i> , 2022, 139, 479-481.	0.6	0
237	New treatment options for the management of acute graft-versus-host disease. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 482-485.	0.3	0
238	Paraneoplastic Pulmonary Alveolar Proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	2.5	0
239	A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. <i>EJHaem</i> , 0, , .	0.4	0
240	Highlights in graft-vs-host disease from the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR: commentary.. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 14, 19-23.	0.3	0
241	Highlights in graft-vs-host disease from the 63rd American Society of Hematology Annual Meeting and Exposition: commentary.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20 Suppl 3, 17-23.	0.3	0